Dr. Stewart discusses study of neoadjuvant axitinib in renal cell carcinoma

In this video, Grant Stewart, MD, discusses the background and findings of the study, “NAXIVA – a phase II neoadjuvant study of axitinib for reducing extent of venous tumor thrombus in clear cell renal cell cancer with venous invasion: translational results.” Stewart is a professor of surgical oncology and honorary consultant urological surgeon at the University of Cambridge, England, United Kingdom.